Acetyl GLP-1 + GIP: The Dual Agonist Peptide Guide UAE (2026)
Acetyl GLP-1 + GIP: The Dual Agonist Peptide Guide UAE (2026)
Acetyl GLP-1 + GIP is a research-grade dual agonist peptide combining GLP-1 receptor and GIP receptor activation — the same dual-agonist mechanism that makes tirzepatide (Mounjaro) one of the most effective weight loss drugs ever trialled. This guide explains the mechanism, how this research peptide compares to tirzepatide, and what UAE researchers need to know about its availability.
Understanding the Dual Agonist Mechanism
GLP-1 (Glucagon-Like Peptide-1) Receptor Agonism
- Stimulates insulin secretion in a glucose-dependent manner (only when blood glucose is elevated)
- Suppresses glucagon secretion — reducing hepatic glucose output
- Slows gastric emptying — prolonging satiety after meals
- Acts on hypothalamic appetite centres (arcuate nucleus) to reduce caloric intake
GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Agonism
- Potentiates insulin secretion additively with GLP-1 — the "incretin effect"
- Promotes fat storage in adipocytes at physiological levels — but at pharmacological doses in combination with GLP-1, enhances fat mobilisation and energy expenditure
- Reduces nausea and GI side effects associated with GLP-1 alone — GIP receptor activation in the area postrema (nausea centre) counteracts GLP-1's emetic effects
- Improves bone metabolism and has reported effects on mood/cognition via central GIP receptors
Acetyl GLP-1 + GIP vs Tirzepatide: What's the Difference?
| Property | Acetyl GLP-1 + GIP | Tirzepatide (Mounjaro) |
|---|---|---|
| Format | Research peptide, injectable vial | Pharmaceutical drug, pre-filled pen |
| Mechanism | Dual GLP-1R + GIPR agonism | Dual GLP-1R + GIPR agonism (GIP-based backbone) |
| Half-life | Short (hours) — research dosing | ~5 days (fatty acid conjugation for weekly dosing) |
| Clinical data | Research compound; no Phase III trials | SURMOUNT trials: 22.5% body weight reduction at 15mg |
| Regulatory status | Research use only | FDA approved (Zepbound for obesity, Mounjaro for T2DM) |
Research Applications
- Dual-agonist mechanism studies in obesity and metabolic syndrome models
- GLP-1 vs GIP receptor contribution analysis (by comparing single vs dual agonist outcomes)
- Beta-cell function and insulin secretion research
- Comparison studies with GLP-1 mono-agonists (semaglutide-class) vs dual agonists
- GI tolerability research (investigating GIP's anti-nausea properties in combination)
Related Products
Buy Acetyl GLP-1 + GIP in Dubai & UAE
5mg and 10mg vials — cGMP sourced, ≥99% HPLC purity, COA available.
Shop Acetyl GLP-1 + GIPFrequently Asked Questions
They share the same receptor targets (GLP-1R and GIPR) but are not the same compound. Tirzepatide (Mounjaro) has a specific molecular structure with a fatty acid conjugation that extends its half-life to ~5 days for once-weekly dosing. Research-grade Acetyl GLP-1 + GIP is a shorter-acting research compound without the pharmaceutical modifications.
GLP-1 receptor activation in the area postrema (brain's nausea centre) is responsible for the nausea and vomiting side effects common with GLP-1 agonists like semaglutide. GIP receptor activation in the same area counteracts this effect, which is why dual agonists like tirzepatide generally have a better GI tolerability profile than GLP-1 mono-agonists at equivalent weight-loss doses.
CoreSup stocks pharmaceutical-grade bacteriostatic water (10ml, 0.9% benzyl alcohol) with same-day delivery across Dubai and all UAE emirates.
Shop Bacteriostatic Water →Disclaimer: This article is for educational and research purposes only. Products mentioned are research compounds not approved by UAE MOHAP or the FDA for human therapeutic use. Nothing herein constitutes medical advice. Consult a licensed UAE healthcare professional before beginning any protocol.
Written by Core Sup Research Team
Core Sup Research Team · Peptide & Supplement Specialists, Dubai UAE
Core Sup's editorial team is composed of specialists in peptide therapy, SARMs, and sports supplementation with direct experience in the UAE market. All content is written to current research standards and reviewed before publication.
Last reviewed: April 2026 · About Core Sup
